Screener
PTC Therapeutics PTCT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| (Loss) income before income tax expense | (2,462) | 929,828 |
| Income tax expense | (347) | (63,266) |
| Net (loss) income attributable to common stockholders | $(2,809) | $866,562 |
| Weighted-average shares outstanding: | ||
| Basic (in shares) | 82,521,023 | 78,115,836 |
| Diluted (in shares) | 82,521,023 | 86,385,922 |
| Net (loss) income per share—basic (in dollars per share) | $(0.03) | $11.09 |
| Net (loss) income per share—diluted (in dollars per share) | $(0.03) | $10.04 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's EPS (diluted)?
- PTC Therapeutics (PTCT) reported EPS (diluted) of -$0.03 in Q1 2026.
- How has PTC Therapeutics's EPS (diluted) changed year-over-year?
- PTC Therapeutics's EPS (diluted) decreased by 100.3% year-over-year, from $10.04 to -$0.03.
- What is the long-term trend for PTC Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2024), PTC Therapeutics's EPS (diluted) has grown at a -13.9% compound annual growth rate (CAGR), from -$7.42 to -$4.73.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about PTC Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude